
Living with Prostate Cancer: PSA testing, treatment hurdles, and a UK screening debate
UK men face rising prostate cancer diagnoses while a National Screening Committee says broad PSA screening isn’t justified due to risks of overdiagnosis and overtreatment, even as awareness grows and access varies by socioeconomic status. The piece follows men like Bulteel, Pennington, Walsh and Hemans, illustrating how PSA testing can detect cancer early but also lead to difficult treatment paths (surgery, radiotherapy, hormone therapy) and significant emotional and relational strain, highlighting disparities in access and the push for targeted screening for at‑risk groups.











